Patents Issued in March 17, 2020
-
Patent number: 10590173Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.Type: GrantFiled: December 20, 2018Date of Patent: March 17, 2020Assignee: Medicago Inc.Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Manon Couture, Lucie Poulin, Louis-Philippe Vezina
-
Patent number: 10590174Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.Type: GrantFiled: July 7, 2017Date of Patent: March 17, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Gilles Gadea, Michael Girardot, Philippe Despres
-
Patent number: 10590175Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.Type: GrantFiled: October 4, 2017Date of Patent: March 17, 2020Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
-
Patent number: 10590176Abstract: The present disclosure provides compositions and methods for preparing engineered porous protein crystals comprising at least one guest molecule.Type: GrantFiled: June 20, 2017Date of Patent: March 17, 2020Assignee: Colorado State University Research FoundationInventors: Christopher D. Snow, Thaddaus R. Huber
-
Patent number: 10590177Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions elated to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.Type: GrantFiled: May 3, 2018Date of Patent: March 17, 2020Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Tapas Das Gupta, Ananda Chakrabarty
-
Patent number: 10590178Abstract: Chimeric double peptide vaccines are disclosed, useful for inducing active immunity against Candida fungal infections. The chimeric peptide comprises an Fba peptide and an Met6 peptide, covalently linked to one another, with or without an intermediate linker. Fba and Met6 are cell surface components of Candida. When used as a vaccine, the chimeric double peptide vaccine induces stronger protective immunity against fungal infection than does the Fba peptide alone, or the Met6 peptide alone, or a mixture (not covalently linked) of the two peptides.Type: GrantFiled: June 19, 2015Date of Patent: March 17, 2020Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Hong Xin
-
Patent number: 10590179Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.Type: GrantFiled: November 9, 2018Date of Patent: March 17, 2020Assignee: Cytlimic Inc.Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
-
Patent number: 10590180Abstract: The present invention discloses immune function development promoters and growth promoters comprising CCL25. The development of immune functions in a subject can be promoted by ingesting an immune function development promoter according to the present invention. Moreover, growth of a subject can be promoted by ingesting a growth promoter according to the present invention.Type: GrantFiled: June 17, 2016Date of Patent: March 17, 2020Assignee: NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITYInventor: Kazutoshi Sayama
-
Patent number: 10590181Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of mutant light-activated ion channels and variants thereof.Type: GrantFiled: April 18, 2015Date of Patent: March 17, 2020Assignee: Massachusetts Institute of TechnologyInventors: Edward S. Boyden, Yongku Peter Cho, Nathan C. Klapoetke, Amy S. Chuong, Fei Chen
-
Patent number: 10590182Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.Type: GrantFiled: February 23, 2016Date of Patent: March 17, 2020Assignee: The Regents of the University of CaliforniaInventors: Wendell A. Lim, Leonardo Morsut, Kole T. Roybal, Justin Thomas Farlow, Satoshi Toda
-
Patent number: 10590183Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: April 12, 2019Date of Patent: March 17, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Patent number: 10590184Abstract: This invention reveals the potential applications of modified porcine plasma fibronectin that could be applied as a safe material for clinical wound healing and tissue repair. In order to seek safe sources of plasma fibronectin for practical consideration in wound dressing, this invention isolated and modified fibronectin from porcine plasma and demonstrated that modified porcine plasma fibronectin has similar ability as homo plasma fibronectin being as a suitable substrate for stimulation of cell adhesion and directed cell migration. The present invention also reveals a material and a pharmaceutical composition enhance wound healing.Type: GrantFiled: September 22, 2017Date of Patent: March 17, 2020Assignee: NATIONAL YANG-MING UNIVERSITYInventor: Jean-Cheng Kuo
-
Patent number: 10590185Abstract: A genetically engineered live bacterium which is adapted to selectively replicate in and colonize a selected tissue type within the mammal, and concurrently produce within the selected tissue type at least one protease-sensitive cytotoxic molecule which is degradable by proteases within the selected tissue type, and at least one protease inhibitor peptide to inhibit the proteases within the selected tissue type from proteolytically degrading the protease sensitive cytotoxic molecule. The combination results in higher concentrations of the cytotoxic molecule local to the colonization, while permitting protease degradation of the cytotoxic molecule further away from the colonization.Type: GrantFiled: May 19, 2017Date of Patent: March 17, 2020Inventor: David Gordon Bermudes
-
Patent number: 10590186Abstract: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric and in aggregated form to a cation exchange material under conditions whereby the immunoglobulin in monomeric form does not bind to the cation exchange material, and recovering the immunoglobulin in monomeric form from the solution after the contact with the cation exchange material.Type: GrantFiled: October 19, 2016Date of Patent: March 17, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Roberto Falkenstein, Claudia Giessel
-
Patent number: 10590187Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.Type: GrantFiled: December 21, 2017Date of Patent: March 17, 2020Assignees: California Institute of Technology, The Rockefeller UniversityInventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
-
Patent number: 10590188Abstract: The present invention provides an antibody which comprises a variable heavy (VH) chain comprising CDR1, CDR2 and CDR3, and/or a variable light (VL) chain comprising CDR1, CDR2 and CDR3, wherein the CDRs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in Tables 1 and 2 or Tables 1 A and 2 A.Type: GrantFiled: June 12, 2015Date of Patent: March 17, 2020Assignee: Queen Mary University of LondonInventors: Michele Bombardieri, Constantino Pitzalis, Elisa Corsiero
-
Patent number: 10590189Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: GrantFiled: July 5, 2017Date of Patent: March 17, 2020Assignee: Alexion Pharmaceuticals, Inc.Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
-
Patent number: 10590190Abstract: The present invention provides anti-C1q antibodies and methods of using the same.Type: GrantFiled: January 4, 2019Date of Patent: March 17, 2020Assignee: Annexon, Inc.Inventors: Arnon Rosenthal, Michael Leviten
-
Patent number: 10590191Abstract: The invention relates to anti-Tau nanobodies.Type: GrantFiled: October 27, 2017Date of Patent: March 17, 2020Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Daniel Fagret, Marcelle Moulin, Catherine Ghezzi, Pascale Perret, Sabine Chierici
-
Patent number: 10590192Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.Type: GrantFiled: October 14, 2015Date of Patent: March 17, 2020Assignee: CELLMID LIMITEDInventors: Maria Halasz, Darren Jones, Nico Mertens, Phillip Cunnah
-
Patent number: 10590193Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: November 16, 2017Date of Patent: March 17, 2020Assignee: Novartis AGInventors: Leonardo Borras, David Urech, Tea Gunde
-
Patent number: 10590194Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: GrantFiled: June 29, 2018Date of Patent: March 17, 2020Assignee: Immatics Biotechnologies GmbHInventors: Claudia Wagner, Leonie Alten, Sebastian Bunk, Dominik Maurer
-
Patent number: 10590195Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: GrantFiled: June 24, 2011Date of Patent: March 17, 2020Assignee: VACCIBODY ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Patent number: 10590196Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.Type: GrantFiled: June 5, 2017Date of Patent: March 17, 2020Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
-
Patent number: 10590197Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.Type: GrantFiled: July 15, 2016Date of Patent: March 17, 2020Assignee: UCB BIOPHARMA SPRLInventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
-
Patent number: 10590198Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 26, 2016Date of Patent: March 17, 2020Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
-
Patent number: 10590199Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.Type: GrantFiled: June 28, 2017Date of Patent: March 17, 2020Assignee: CHECKPOINT THERAPEUTICS, INC.Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
-
Patent number: 10590201Abstract: Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.Type: GrantFiled: January 16, 2018Date of Patent: March 17, 2020Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard M. Siegel, Francoise Meylan, Yun-Jeong Song
-
Patent number: 10590202Abstract: A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.Type: GrantFiled: November 19, 2013Date of Patent: March 17, 2020Assignee: BALIOPHARM AGInventors: Andreas Herrmann, Ludger Grosse-Hovest
-
Patent number: 10590203Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: GrantFiled: August 11, 2017Date of Patent: March 17, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
-
Patent number: 10590204Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.Type: GrantFiled: February 8, 2018Date of Patent: March 17, 2020Assignee: KATINGER GMBHInventors: Hermann Katinger, Renate Kunert, Thomas Sterovsky, Thomas Hemetsberger
-
Patent number: 10590205Abstract: Provided herein are compositions, which exhibit diagnostic capabilities and allow to rapidly add functionality to adoptive immunotherapy. The compositions include isolated nucleic acids encoding proteins including antibody regions capable of binding compounds including a peptidyl moiety (e.g., a meditope). The recombinant proteins provided herein are useful, inter alia, for a broad variety of therapeutic and diagnostic purposes. For example, the recombinant proteins provided herein including embodiments thereof may be used as non-invasive means to characterize chimeric antigen receptor (CAR) T cells before and/or during treatment of diseases (e.g., cancer).Type: GrantFiled: February 15, 2017Date of Patent: March 17, 2020Assignee: CITY OF HOPEInventors: John C. Williams, Christine Brown
-
Patent number: 10590206Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.Type: GrantFiled: January 9, 2014Date of Patent: March 17, 2020Assignee: GENMAB A/SInventors: Aran Frank Labrijn, Joyce Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
-
Patent number: 10590207Abstract: The present invention is directed to a process for obtaining at least one of fucoidan and laminarin from live, harvested seaweed, wherein the process comprises the steps of: (i) harvesting seaweed comprising fucoidan and laminarin to obtain live, harvested seaweed, wherein the live, harvested seaweed exudes to form an exudate solution; (ii) collecting the exudate solution from the live, harvested seaweed, wherein the fucoidan and laminarin are dissolved in the exudate solution; and (iii) separating the at least one of fucoidan or laminarin from the exudate solution.Type: GrantFiled: November 18, 2011Date of Patent: March 17, 2020Inventors: Finn Hjelland, Arne Henning Andersen, Hui S. Yang
-
Patent number: 10590208Abstract: A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer to form a reactive polymer, and (ii) reacting the reactive polymer with an imine compound containing a cyano group.Type: GrantFiled: October 1, 2014Date of Patent: March 17, 2020Assignee: Bridgestone CorporationInventors: Steven Luo, Joshua S. Dickstein
-
Patent number: 10590209Abstract: A catalyst composition for selectively hydrogenating a conjugated diene polymer in a homogeneous system is provided, wherein the conjugated diene polymer comprises a conjugated diene monomer or a combination of a conjugated diene monomer and a vinyl aromatic monomer. The catalyst composition includes the catalyst components of (a) a titanium compound; (b) an organometallic compound; and (c) an oligomer containing a polyglycol segment. The hydrogenated polymer produced using the catalyst composition and the method thereof is also provided.Type: GrantFiled: November 28, 2017Date of Patent: March 17, 2020Assignee: TSRC CorporationInventors: Kuoyu Weng, Fengyu Yang, Wenhsien Wen, Ching Ting, Ting-Yu Lee
-
Patent number: 10590210Abstract: A method for producing chlorinated polyvinyl chloride includes bringing chlorine gas into contact with a mixture comprising a polyvinyl chloride powder and at least one inorganic filler; and irradiating the mixture with UV light to perform a chlorination reaction. At least one inorganic filler is selected from the group consisting of silica, carbon black, and talc.Type: GrantFiled: August 22, 2018Date of Patent: March 17, 2020Assignee: KANEKA CORPORATIONInventors: Junichi Hirota, Yoshito Takeuchi, Naoki Deguchi
-
Patent number: 10590211Abstract: A method for producing a solid catalyst component includes bringing a magnesium compound, a titanium halide compound, and one or more internal electron donor compounds into contact with each other to effect a reaction; washing the resulting product with a first inert organic wash solvent that does not have reactivity with the titanium halide compound, and has a solubility parameter (SP) of 8.0 to 9.0; washing the resulting intermediate product in the absence of the titanium halide compound with a second inert organic wash solvent that includes a hydrocarbon compound and does not have reactivity with the titanium halide compound, but has a solubility parameter (SP) of more than 9.0; and washing the resulting product in the absence of the titanium halide compound with a third inert organic wash solvent that does not have reactivity with the titanium halide compound, and has a solubility parameter (SP) of less than 8.0.Type: GrantFiled: December 19, 2017Date of Patent: March 17, 2020Assignee: TOHO TITANIUM CO., LTD.Inventors: Motoki Hosaka, Toshihiko Sugano, Tsutomu Uzawa
-
Patent number: 10590212Abstract: This invention relates to new multimodal and/or broad molecular weight high density polyethylene polymers. The polymers may be made in a single reactor, preferably a gas phase reactor using a dual catalyst system comprising a pyridyldiamido transition metal compound, a metallocene compound, a support, and optionally an activator.Type: GrantFiled: April 20, 2016Date of Patent: March 17, 2020Assignee: ExxonMobil Chemical Patents Inc.Inventors: Antonios K. Doufas, David F. Sanders, Alexander I. Norman, Matthew W. Holtcamp, Keith R. Green, Rohan A. Hule, Derek W. Thurman
-
Patent number: 10590213Abstract: Disclosed herein are ethylene-based polymers generally characterized by a density of at least 0.94 g/cm3, a high load melt index from 4 to 20 g/10 min, a zero-shear viscosity at 190° C. from 20,000 to 400,000 kPa-sec, and a relaxation time at 190° C. from 225 to 3000 sec. These ethylene polymers can be produced by peroxide-treating a broad molecular weight distribution Ziegler-catalyzed resin, and can be used in large diameter, thick wall pipes and other end-use applications.Type: GrantFiled: March 13, 2018Date of Patent: March 17, 2020Assignee: Chevron Phillips Chemical Company LPInventors: Vivek Rohatgi, Ashish M. Sukhadia, Yongwoo Inn, Elizabeth M. Lanier
-
Patent number: 10590214Abstract: The various embodiments of the invention provide, a magnesium titanium polymerization procatalyst, methods for making and using the same.Type: GrantFiled: June 6, 2018Date of Patent: March 17, 2020Assignee: NOVA Chemicals (International) S.A.Inventors: Qinyan Wang, Helena Ouskine, Mohamed Aiffa, Amy Baltimore, Holly Severin, Perry Dewit, Steven Clemens, Lawrence Martin Josef Van Asseldonk, Isam Jaber
-
Patent number: 10590215Abstract: The present disclosure provides a novel transition metal compound having excellent structural stability together with polymerization reactivity, and thereby is useful as a catalyst in preparing an olefin-based polymer, particularly, a high molecular weight and low density olefin-based polymer, and a catalyst composition including the same.Type: GrantFiled: April 18, 2019Date of Patent: March 17, 2020Assignee: LG CHEM, LTD.Inventors: Yoon Hee Cho, Jin Sam Gong, Jung Ho Jun, Choong Hoon Lee, Seung Hwan Jung
-
Patent number: 10590216Abstract: The present invention relates to a method for producing a vinyl chloride-based resin composition which exhibits good processability due to excellent solubility in a solvent, can implement excellent transparency in products produced, and improves the glossiness of a coating film when used as an ink binder, thereby being capable of being used as a high-quality adhesive and ink binder, and a method for producing the same.Type: GrantFiled: November 25, 2016Date of Patent: March 17, 2020Assignee: HANWHA CHEMICAL CORPORATIONInventors: Ji Won Kim, Jeong Hwan Ko, Paul Kang
-
Patent number: 10590217Abstract: Provided are a curable compound, a photoinitiator, and a curable resin composition comprising at least two types of thermal initiators, each having different initiation reaction temperature. Since the curable resin composition can improve a curing rate while having a high conversion rate, the curable resin composition is suitable for manufacturing thick films.Type: GrantFiled: December 27, 2012Date of Patent: March 17, 2020Assignee: LG HAUSYS, LTD.Inventors: Dong Kwan Kim, Min Hee Lee
-
Patent number: 10590218Abstract: Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a crosslinker monomer or oligomer having more than two polymerizable groups. Devices formed from radiopaque polymer compositions are also provided.Type: GrantFiled: March 14, 2014Date of Patent: March 17, 2020Assignee: ENDOSHAPE, INC.Inventors: Stephen D. Goodrich, Jeffrey P. Castleberry
-
Patent number: 10590219Abstract: A retardation material-forming resin composition for providing an orientation material that has high photoreaction efficiency and with which a polymerizable crystal can be aligned in a highly sensitive manner. A retardation material-forming resin composition being thermally curable wherein including a resin (component (A)) having a photo-aligning group to which a thermally reactive moiety is bonded directly or connected via a linking group; an orientation material obtained by use of the composition, and a retardation material formed by use of a cured film obtained from the composition.Type: GrantFiled: August 17, 2018Date of Patent: March 17, 2020Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Shojiro Yukawa, Jun Ito, Kohei Goto, Yuta Kanno, Hiroyuki Omura, Tadashi Hatanaka
-
Patent number: 10590220Abstract: The present disclosure provides for new photoalignment (co)polymer materials which demonstrate improved adhesion to a substrate. The (co)polymeric structure includes at least one photochemically active chromophore and at least one adhesion promoter group. Articles of manufacture, optical elements, ophthalmic elements and liquid crystal cells which include at least one photoalignment layer made from the photoalignment (co)polymer materials and methods for formation are also disclosed.Type: GrantFiled: October 21, 2016Date of Patent: March 17, 2020Assignee: Transitions Optical, Inc.Inventors: Gobinda Saha, Anil Kumar
-
Patent number: 10590221Abstract: Provided is a modified diene based polymer in which a diene based polymer is graft modified with a polyether having a mercapto group attached via diurethane bonding. Formation of diurethane bonding is performed by allowing sequential reactions of two species of hydroxyl group-containing compounds with an diisocyanate compound. By adding the modified diene based polymer to a silica-containing rubber composition for automobile pneumatic tires, the dispersibility of silica compounded in the rubber composition can be improved, and a property inherent in silica which simultaneously allows a reduction of rolling resistance and a stability on wet road surfaces can be sufficiently effected.Type: GrantFiled: December 2, 2015Date of Patent: March 17, 2020Assignee: The Yokohama Rubber Co., Ltd.Inventors: Kazuya Uenishi, Takahiro Okamatsu, Ryota Takahashi
-
Patent number: 10590222Abstract: The present invention is to provide a thermoplastic resin composition capable of obtaining a molded article that is excellent in appearance after laser welding and a color tone and has sufficient impact property as a resin member. In addition, the present invention is to provide a molded article that is excellent in appearance after laser welding and a color tone and has sufficient impact resistance as a resin member. As a result of intensive studies, the present inventors have found that the above problems can be solved by controlling a thermoplastic resin composition containing rubber-containing graft copolymer to have appropriate reflectance in the visible light and absorptivity in the near-infrared region, and have completed the present invention.Type: GrantFiled: February 3, 2017Date of Patent: March 17, 2020Assignee: Techno-UMG Co., Ltd.Inventors: Ichiro Kamata, Hiroyuki Atsuta
-
Patent number: 10590223Abstract: A polyphenylene ether resin composition includes (A) a modified polyphenylene ether that is end-modified with a substituent having a carbon-carbon unsaturated double bond, and (B) a crosslinking agent having a carbon-carbon unsaturated double bond. The crosslinking agent serving as component (B) includes from 50 to 100 mass % of (B-1) divinylbenzene and (B-2) polybutadiene. Components (A) and (B) are included in a ratio therebetween, expressed as the mass ratio (A):(B), of from 65:35 to 95:5. Components (B-1) and (B-2) are included in a ratio therebetween, expressed as the mass ratio (B-1):(B-2), of from 1:100 to 1.5:1.Type: GrantFiled: June 13, 2014Date of Patent: March 17, 2020Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.Inventors: Yuki Kitai, Hiroaki Fujiwara, Hirosuke Saito